NASDAQ:ZGNX

Zogenix Competitors

$19.00
-0.66 (-3.36 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.75
Now: $19.00
$19.94
50-Day Range
$18.52
MA: $20.08
$22.16
52-Week Range
$17.20
Now: $19.00
$32.42
Volume384,705 shs
Average Volume845,616 shs
Market Capitalization$1.06 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.6

Competitors

Zogenix (NASDAQ:ZGNX) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying ZGNX stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Zogenix, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), and Bristol-Myers Squibb (BMY).

Johnson & Johnson (NYSE:JNJ) and Zogenix (NASDAQ:ZGNX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.

Earnings & Valuation

This table compares Johnson & Johnson and Zogenix's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.06 billion5.21$15.12 billion$8.6818.69
Zogenix$3.65 million290.13$-419,500,000.00($3.90)-4.87

Johnson & Johnson has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Johnson & Johnson has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Johnson & Johnson and Zogenix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson031102.79
Zogenix01502.83

Johnson & Johnson currently has a consensus target price of $182.6154, suggesting a potential upside of 12.56%. Zogenix has a consensus target price of $58.25, suggesting a potential upside of 206.58%. Given Zogenix's stronger consensus rating and higher probable upside, analysts clearly believe Zogenix is more favorable than Johnson & Johnson.

Insider & Institutional Ownership

67.3% of Johnson & Johnson shares are held by institutional investors. Comparatively, 96.6% of Zogenix shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by company insiders. Comparatively, 3.5% of Zogenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Johnson & Johnson and Zogenix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson21.01%34.64%13.40%
Zogenix-8,758.48%-53.91%-36.49%

Summary

Johnson & Johnson beats Zogenix on 8 of the 14 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Zogenix (NASDAQ:ZGNX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Risk and Volatility

Pfizer has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.

Valuation & Earnings

This table compares Pfizer and Zogenix's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion4.16$16.27 billion$2.9513.07
Zogenix$3.65 million290.13$-419,500,000.00($3.90)-4.87

Pfizer has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.4% of Pfizer shares are owned by institutional investors. Comparatively, 96.6% of Zogenix shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 3.5% of Zogenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Pfizer and Zogenix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer17.85%24.88%9.32%
Zogenix-8,758.48%-53.91%-36.49%

Analyst Recommendations

This is a summary of current recommendations for Pfizer and Zogenix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer010302.23
Zogenix01502.83

Pfizer currently has a consensus price target of $38.5714, indicating a potential upside of 0.00%. Zogenix has a consensus price target of $58.25, indicating a potential upside of 206.58%. Given Zogenix's stronger consensus rating and higher possible upside, analysts clearly believe Zogenix is more favorable than Pfizer.

Merck & Co., Inc. (NYSE:MRK) and Zogenix (NASDAQ:ZGNX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Institutional and Insider Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 96.6% of Zogenix shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 3.5% of Zogenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Merck & Co., Inc. and Zogenix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.24.33%53.83%16.83%
Zogenix-8,758.48%-53.91%-36.49%

Risk & Volatility

Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Merck & Co., Inc. and Zogenix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021102.85
Zogenix01502.83

Merck & Co., Inc. currently has a consensus price target of $96.2727, indicating a potential upside of 24.27%. Zogenix has a consensus price target of $58.25, indicating a potential upside of 206.58%. Given Zogenix's higher probable upside, analysts plainly believe Zogenix is more favorable than Merck & Co., Inc..

Earnings and Valuation

This table compares Merck & Co., Inc. and Zogenix's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.19$9.84 billion$5.1914.93
Zogenix$3.65 million290.13$-419,500,000.00($3.90)-4.87

Merck & Co., Inc. has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Summary

Merck & Co., Inc. beats Zogenix on 9 of the 14 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Zogenix (NASDAQ:ZGNX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

67.5% of AbbVie shares are owned by institutional investors. Comparatively, 96.6% of Zogenix shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 3.5% of Zogenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

AbbVie has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for AbbVie and Zogenix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie121302.75
Zogenix01502.83

AbbVie currently has a consensus price target of $115.75, suggesting a potential upside of 7.27%. Zogenix has a consensus price target of $58.25, suggesting a potential upside of 206.58%. Given Zogenix's stronger consensus rating and higher possible upside, analysts plainly believe Zogenix is more favorable than AbbVie.

Profitability

This table compares AbbVie and Zogenix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie18.16%439.24%13.22%
Zogenix-8,758.48%-53.91%-36.49%

Earnings and Valuation

This table compares AbbVie and Zogenix's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion5.72$7.88 billion$8.9412.07
Zogenix$3.65 million290.13$-419,500,000.00($3.90)-4.87

AbbVie has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Zogenix on 8 of the 14 factors compared between the two stocks.

Zogenix (NASDAQ:ZGNX) and Eli Lilly and (NYSE:LLY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Earnings & Valuation

This table compares Zogenix and Eli Lilly and's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zogenix$3.65 million290.13$-419,500,000.00($3.90)-4.87
Eli Lilly and$22.32 billion8.13$8.32 billion$6.0431.33

Eli Lilly and has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Zogenix and Eli Lilly and, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zogenix01502.83
Eli Lilly and041102.73

Zogenix presently has a consensus price target of $58.25, suggesting a potential upside of 206.58%. Eli Lilly and has a consensus price target of $196.40, suggesting a potential upside of 3.78%. Given Zogenix's stronger consensus rating and higher possible upside, analysts clearly believe Zogenix is more favorable than Eli Lilly and.

Institutional and Insider Ownership

96.6% of Zogenix shares are held by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are held by institutional investors. 3.5% of Zogenix shares are held by insiders. Comparatively, 0.1% of Eli Lilly and shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Zogenix and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zogenix-8,758.48%-53.91%-36.49%
Eli Lilly and24.01%166.45%15.18%

Volatility and Risk

Zogenix has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.

Summary

Eli Lilly and beats Zogenix on 8 of the 14 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Zogenix (NASDAQ:ZGNX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Bristol-Myers Squibb and Zogenix's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.59$3.44 billion$4.6913.96
Zogenix$3.65 million290.13$-419,500,000.00($3.90)-4.87

Bristol-Myers Squibb has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

72.4% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 96.6% of Zogenix shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Comparatively, 3.5% of Zogenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Bristol-Myers Squibb has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Bristol-Myers Squibb and Zogenix, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb021312.94
Zogenix01502.83

Bristol-Myers Squibb presently has a consensus target price of $74.60, indicating a potential upside of 13.96%. Zogenix has a consensus target price of $58.25, indicating a potential upside of 206.58%. Given Zogenix's higher probable upside, analysts clearly believe Zogenix is more favorable than Bristol-Myers Squibb.

Profitability

This table compares Bristol-Myers Squibb and Zogenix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-0.11%27.48%10.77%
Zogenix-8,758.48%-53.91%-36.49%

Summary

Bristol-Myers Squibb beats Zogenix on 9 of the 15 factors compared between the two stocks.


Zogenix Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.7$162.24-1.1%$427.13 billion$82.06 billion25.51Upcoming Earnings
Pfizer logo
PFE
Pfizer
2.3$38.57-2.5%$215.13 billion$51.75 billion24.88Analyst Revision
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.2$77.47-1.0%$196.03 billion$46.84 billion17.14Increase in Short Interest
Analyst Revision
News Coverage
AbbVie logo
ABBV
AbbVie
2.8$107.91-0.9%$190.44 billion$33.27 billion22.81Analyst Revision
Eli Lilly and logo
LLY
Eli Lilly and
2.1$189.25-1.8%$181.49 billion$22.32 billion30.92Analyst Revision
News Coverage
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$65.46-1.6%$146.23 billion$26.15 billion-595.04Analyst Upgrade
Decrease in Short Interest
Analyst Revision
Zoetis logo
ZTS
Zoetis
2.2$167.63-1.3%$79.62 billion$6.26 billion49.74Increase in Short Interest
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$41.87-0.5%$25.42 billionN/A0.00Dividend Announcement
Insider Selling
Increase in Short Interest
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$93.27-0.3%$20.90 billion$1.30 billion25.48Insider Selling
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$168.90-0.3%$9.51 billion$2.16 billion53.28Analyst Report
Perrigo logo
PRGO
Perrigo
2.3$41.62-1.1%$5.56 billion$4.84 billion-693.55
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00-1.9%$3.46 billion$114.62 million-7.66Analyst Report
Insider Selling
News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07-5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
High Trading Volume
News Coverage
Gap Up
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77-0.7%$2.67 billion$306.49 million25.58
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.70-0.5%$1.68 billion$392.76 million13.15Analyst Upgrade
Analyst Revision
Endo International logo
ENDP
Endo International
1.3$6.26-3.4%$1.44 billion$2.91 billion-9.21
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72News Coverage
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$8.01-1.4%$375.61 million$16.54 million-3.26News Coverage
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.42-1.5%$344.95 million$111.39 million24.43News Coverage
Lannett logo
LCI
Lannett
2.0$4.76-0.2%$197.07 million$545.74 million-6.61
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.28-1.2%$171.45 million$15.96 million-2.59
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$2.99-1.7%$44.61 million$47.53 million-13.59
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.